SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH

Key Points

• SWS Partners cut its stake in Guardant Health by 18.3% in Q4, selling 17,347 shares and holding 77,209 shares worth $7.89 million, which represents about 1.5% of SWS's portfolio.
• Guardant reported Q4 EPS of -$0.50 (missed estimates by $0.07) while revenue rose 39.4% to $281.3 million, and analysts are largely upbeat with a MarketBeat consensus of "Moderate Buy" and an average target price of $125.95.
• Insider selling has been notable recently, with 23,250 shares sold (~$2.51 million) in the past 90 days; corporate insiders now own 6.10% of the company.

SWS Partners decreased its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 77,209 shares of the company's stock after selling 17,347 shares during the quarter. Guardant Health accounts for approximately 1.5% of SWS Partners' investment portfolio, making the stock its 17th biggest holding. SWS Partners owned 0.06% of Guardant Health worth $7,886,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in GH. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health in the fourth quarter worth approximately $28,000. Sound Income Strategies LLC bought a new position in shares of Guardant Health in the third quarter valued at approximately $38,000. Optiver Holding B.V. boosted its position in shares of Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company's stock valued at $48,000 after buying an additional 465 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Guardant Health by 38.8% during the fourth quarter. GAMMA Investing LLC now owns 808 shares of the company's stock valued at $83,000 after buying an additional 226 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in Guardant Health by 19.5% during the third quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after buying an additional 138 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Trading Down 1.3%

Shares of Guardant Health stock opened at $91.15 on Thursday. The business's fifty day simple moving average is $97.96 and its 200 day simple moving average is $92.15. Guardant Health, Inc. has a 12 month low of $36.36 and a 12 month high of $120.74. The firm has a market capitalization of $11.96 billion, a P/E ratio of -27.54 and a beta of 1.67.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. Guardant Health's revenue for the quarter was up 39.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.62) EPS. Analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GH. Stifel Nicolaus increased their price target on Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 20th. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Friday, February 20th. Robert W. Baird assumed coverage on shares of Guardant Health in a report on Tuesday, February 17th. They issued an "outperform" rating and a $120.00 target price for the company. Leerink Partners raised their price target on shares of Guardant Health from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Friday, February 20th. Finally, Raymond James Financial restated an "outperform" rating and set a $129.00 price target on shares of Guardant Health in a report on Monday, February 23rd. Twenty equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $125.95.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 348 shares of the business's stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total value of $30,655.32. Following the transaction, the director directly owned 8,394 shares in the company, valued at $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the business's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares in the company, valued at approximately $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 23,250 shares of company stock worth $2,512,917 in the last ninety days. Corporate insiders own 6.10% of the company's stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.